Jaguar Health, Inc. (JAGX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Jaguar Health, Inc. on November 17, 2025. The filing details material definitive agreements and unregistered sales of equity securities involving the Company and its wholly-owned subsidiary, Napo Pharmaceuticals, Inc. The primary counterparties are Iliad Research and Trading, L.P., Uptown Capital, LLC, and Streeterville Capital, LLC.
Key Financial Metrics and Obligations
- Royalty Interests: The Company holds three royalty interests with an original principal amount of $12 million each ($36 million total) with Iliad, Uptown, and Streeterville.
- Debt Instrument: A secured promissory note with an original principal amount of $6,220,812.50 is held by Streeterville.
- Equity Issuance: The Company issued 361,271 shares of common stock in an exchange transaction.
- Preferred Stock: 25 shares of Series M Perpetual Preferred Stock were cancelled and retired.
Material Changes and Agreements
Royalty Interest Global Amendments No. 3: Effective April 1, 2026, the monthly royalty payment under each of the three royalty interests will be the greater of (a) $750,000.00 or (b) the actual royalty payment amount calculated under the original terms. This establishes a minimum monthly cash outflow of $2.25 million ($750,000 x 3) starting in April 2026.
Note Amendment No. 2: The maturity date of the $6,220,812.50 secured promissory note held by Streeterville has been extended to April 1, 2026.
Exchange Transaction: The Company exchanged 25 outstanding shares of Series M Preferred Stock held by Streeterville for 361,271 shares of common stock. The preferred shares were cancelled upon completion. This transaction was conducted under Section 3(a)(9) of the Securities Act.
Outlook, Risks, and Management Commentary
The filing does not provide specific forward-looking guidance, revenue projections, or management commentary regarding future operational performance. The primary risk highlighted is the increased fixed financial obligation beginning April 1, 2026, due to the minimum royalty payment floors. The extension of the note maturity to April 1, 2026, aligns the debt maturity with the new royalty payment structure.
Key Facts for Investor Verification
- Verify the Company's current cash position and liquidity to support the new minimum monthly royalty obligation of $2.25 million starting April 1, 2026.
- Confirm the total outstanding principal of the secured promissory note and any accrued interest due at the new maturity date of April 1, 2026.
- Review the dilution impact of the 361,271 common shares issued to Streeterville.
- Examine the full text of the Royalty Interest Global Amendments (Exhibits 4.1, 4.2, 4.3) to understand the calculation of the "actual Royalty Payment amount" that may exceed the $750,000 floor.